DrugPatentWatch Database Preview
Genus Lifesciences Company Profile
What is the competitive landscape for GENUS LIFESCIENCES, and what generic alternatives to GENUS LIFESCIENCES drugs are available?
GENUS LIFESCIENCES has nine approved drugs.
There are seven US patents protecting GENUS LIFESCIENCES drugs.
There are forty-three patent family members on GENUS LIFESCIENCES drugs in twenty-three countries and nineteen supplementary protection certificates in ten countries.
Summary for Genus Lifesciences
| International Patents: | 43 |
| US Patents: | 7 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 9 |
Drugs and US Patents for Genus Lifesciences
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | RX | Yes | No | 6,926,907 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-007 | Jun 6, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-001 | Jun 6, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-011 | Jun 6, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | RX | Yes | No | 9,364,439 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-006 | Jun 6, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-004 | Jun 6, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 81 mg/40 mg | ➤ Subscribe | 2016-10-14 |
International Patents for Genus Lifesciences Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Norway | 20035275 | ➤ Sign Up |
| Norway | 333836 | ➤ Sign Up |
| Eurasian Patent Organization | 028049 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2013101897 | ➤ Sign Up |
| Mexico | 2011002515 | ➤ Sign Up |
| Japan | 2004536809 | ➤ Sign Up |
| Mexico | 2014007935 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Genus Lifesciences Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB12/028 | United Kingdom | ➤ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| C/GB08/020 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023. |
| C0025 | Belgium | ➤ Sign Up | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
| C0026 | France | ➤ Sign Up | PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220 |
| C0038 | France | ➤ Sign Up | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| C/GB10/012 | United Kingdom | ➤ Sign Up | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| C/GB98/031 | United Kingdom | ➤ Sign Up | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
